{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:53:41Z","timestamp":1790758421441,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Cardiol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00246-025-03880-y","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T01:49:26Z","timestamp":1745891366000},"page":"1077-1082","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety of Direct Oral Anticoagulants in Transcatheter Pulmonary Valves: A Pediatric Institution\u2019s Experience"],"prefix":"10.1007","volume":"47","author":[{"given":"Daniela","family":"Barisano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwen","family":"Nance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle E.","family":"Gleason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary M.","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6637-625X","authenticated-orcid":false,"given":"Joshua W.","family":"Branstetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"3880_CR1","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1093\/eurheartj\/ehm181","volume":"28","author":"L Coats","year":"2007","unstructured":"Coats L, Khambadkone S, Derrick G, Hughes M, Jones R, Mist B, Pellerin D, Marek J, Deanfield JE, Bonhoeffer P, Taylor AM (2007) Physiological consequences of percutaneous pulmonary valve implantation: the different behaviour of volume- and pressure-overloaded ventricles. Eur Heart J 28:1886\u20131893","journal-title":"Eur Heart J"},{"key":"3880_CR2","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ijcard.2014.03.002","volume":"173","author":"J M\u00fcller","year":"2014","unstructured":"M\u00fcller J, Engelhardt A, Fratz S, Eicken A, Ewert P, Hager A (2014) Improved exercise performance and quality of life after percutaneous pulmonary valve implantation. Int J Cardiol 173:388\u2013392","journal-title":"Int J Cardiol"},{"key":"3880_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40268-016-0124-1","volume":"16","author":"AR Dur\u00e3es","year":"2016","unstructured":"Dur\u00e3es AR, de Souza RP, de Almeida NB et al (2016) Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA pilot study. Drugs R D 16:149\u2013154","journal-title":"Drugs R D"},{"issue":"4","key":"3880_CR4","first-page":"e001779","volume":"8","author":"A Latib","year":"2015","unstructured":"Latib A, Naganuma T, Abdel-Wahab M et al (2015) Treatment and clinical outcomes of transcatheter heart valve thrombosis. Circ: Cardiovasc Interv 8(4):e001779","journal-title":"Circ: Cardiovasc Interv"},{"issue":"19","key":"3880_CR5","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018506","volume":"9","author":"AE Kostyunin","year":"2020","unstructured":"Kostyunin AE, Yuzhalin AE, Rezvova MA et al (2020) Degeneration of bioprosthetic heart valves: update 2020. J Am Heart Assoc 9(19):e018506","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"3880_CR6","first-page":"e011480","volume":"15","author":"S Garcia","year":"2022","unstructured":"Garcia S, Fukui M, Dworak MW, Okeson BK, Garberich R, Hashimoto G, Sato H, Cavalcante JL, Bapat VN, Lesser J, Cheng V (2022) Clinical impact of hypoattenuating leaflet thickening after transcatheter aortic valve replacement. Circ: Cardiovasc Interv 15(3):e011480","journal-title":"Circ: Cardiovasc Interv"},{"issue":"4","key":"3880_CR7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jacc.2020.11.035","volume":"77","author":"CM Otto","year":"2021","unstructured":"Otto CM, Nishimura RA, Bonow RO et al (2021) 2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 77(4):450\u2013500","journal-title":"J Am Coll Cardiol"},{"key":"3880_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.jtcvs.2009.10.064","volume":"139","author":"AW ElBardissi","year":"2010","unstructured":"ElBardissi AW, DiBardino DJ, Chen FY et al (2010) Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm? J Thorac Cardiovasc Surg 139:1137\u20131145","journal-title":"J Thorac Cardiovasc Surg"},{"key":"3880_CR9","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jtcvs.2004.11.028","volume":"129","author":"TM Sundt","year":"2005","unstructured":"Sundt TM, Zehr KJ, Dearani JA et al (2005) Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement? J Thorac Cardiovasc Surg 129:1024\u20131031","journal-title":"J Thorac Cardiovasc Surg"},{"key":"3880_CR10","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/0735-1097(94)00563-6","volume":"25","author":"M Heras","year":"1995","unstructured":"Heras M, Chesebro JH, Fuster V et al (1995) High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 25:1111\u20131119","journal-title":"J Am Coll Cardiol"},{"key":"3880_CR11","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1001\/jama.2012.54506","volume":"308","author":"C M\u00e9rie","year":"2012","unstructured":"M\u00e9rie C, K\u00f8ber L, Skov Olsen P et al (2012) Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA 308:2118\u20132125","journal-title":"JAMA"},{"issue":"22","key":"3880_CR12","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1016\/j.jcin.2020.09.013","volume":"13","author":"H Kawashima","year":"2020","unstructured":"Kawashima H, Watanabe Y, Hioki H et al (2020) OCEAN-TAVI Investigator. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after TAVR. JACC Cardiovasc Interv 13(22):2587\u20132597","journal-title":"JACC Cardiovasc Interv"},{"issue":"15","key":"3880_CR13","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.jcin.2021.05.025","volume":"14","author":"R Didier","year":"2021","unstructured":"Didier R, Lhermusier T, Auffret V et al (2021) STOP-AS and France-TAVI. TAVR Patients requiring anticoagulation: direct oral anticoagulant or vitamin K antagonist? JACC Cardiovasc Interv 14(15):1704\u20131713","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"3880_CR14","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","volume":"7","author":"C Male","year":"2020","unstructured":"Male C, Lensing AW, Palumbo JS et al (2020) Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol 7(1):e18\u201327","journal-title":"Lancet Haematol"},{"issue":"22","key":"3880_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.021765","volume":"10","author":"BW McCrindle","year":"2021","unstructured":"McCrindle BW, Michelson AD, Van Bergen AH et al (2021) Thromboprophylaxis for children post-Fontan procedure: insights from the UNIVERSE study. J Am Heart Assoc 10(22):e021765","journal-title":"J Am Heart Assoc"},{"issue":"22","key":"3880_CR16","doi-asserted-by":"publisher","first-page":"5908","DOI":"10.1182\/bloodadvances.2021005681","volume":"6","author":"LR Brand\u00e3o","year":"2022","unstructured":"Brand\u00e3o LR, Tartakovsky I, Albisetti M et al (2022) Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia. Blood Adv 6(22):5908\u20135923","journal-title":"Blood Adv"},{"key":"3880_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ahj.2019.08.002","volume":"217","author":"RM Payne","year":"2019","unstructured":"Payne RM, Burns KM, Glatz AC, Li D, Li X, Monagle P, Newburger JW, Swan EA, Wheaton O, Male C (2019) Pediatric Heart Network Investigators. A multi-national trial of a direct oral anticoagulant in children with cardiac disease: design and rationale of the safety of ApiXaban on pediatric heart disease on the prevention of embolism (SAXOPHONE) study. Am Heart J 217:52\u201363","journal-title":"Am Heart J"},{"key":"3880_CR18","unstructured":"Collet JP. Anti-Thrombotic strategy to lower all cardiovascular and neurologic ischemic and hemorrhagic events after trans-aortic valve implantation for aortic stenosis - ATLANTIS. Presented at the American College of Cardiology Virtual Annual Scientific Session (ACC 2021). May 15, 2021."},{"key":"3880_CR19","doi-asserted-by":"publisher","first-page":"A17277","DOI":"10.1161\/circ.132.suppl_3.17277","volume":"132","author":"SD Pokorney","year":"2015","unstructured":"Pokorney SD, Rao MP, Wojdyla DM et al (2015) Apixaban use in patients with atrial fibrillation with bioprosthetic valves: insights from ARISTOTLE. Circulation 132:A17277","journal-title":"Circulation"},{"issue":"8","key":"3880_CR20","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","volume":"132","author":"A Avezum","year":"2015","unstructured":"Avezum A, Lopes RD, Schulte PJ et al (2015) Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation 132(8):624\u2013632","journal-title":"Circulation"},{"issue":"228","key":"3880_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.thromres.2023.06.013","volume":"13","author":"CT Cohen","year":"2023","unstructured":"Cohen CT, Zobeck M, Han H et al (2023) Bleeding outcomes and management of supratherapeutic episodes secondary to warfarin in children: a single center 10-year experience. Thromb Res 13(228):148","journal-title":"Thromb Res"},{"issue":"4","key":"3880_CR22","first-page":"148","volume":"10","author":"H Konsek","year":"2023","unstructured":"Konsek H, Sherard C, Bisbee C et al (2023) Growing heart valve implants for children. J Cardiovasc Dev Dis 10(4):148","journal-title":"J Cardiovasc Dev Dis"}],"container-title":["Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-025-03880-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00246-025-03880-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-025-03880-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:02:09Z","timestamp":1770879729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00246-025-03880-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3880"],"URL":"https:\/\/doi.org\/10.1007\/s00246-025-03880-y","relation":{},"ISSN":["0172-0643","1432-1971"],"issn-type":[{"value":"0172-0643","type":"print"},{"value":"1432-1971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to disclose for the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}